IVDR Performance Study Requirements: Application vs Notification, Timelines, and Reporting
Comprehensive guide to IVDR Chapter VI performance studies: Article 58 application triggers, Article 70 PMPF notifications, Article 66 timelines, leftover samples, and safety reporting.
In vitro diagnostic (IVD) manufacturers operating under the European In Vitro Diagnostic Medical Devices Regulation (Regulation (EU) 2017/746 - IVDR) frequently struggle with clinical evidence generation. Unlike general medical devices governed by the EU MDR (Regulation (EU) 2017/745), where clinical investigations typically involve direct physical contact with patients, IVDs generate data by examining specimens derived from the human body.
This fundamental biological distinction creates widespread confusion among regulatory affairs teams, clinical project managers, and diagnostic assay developers. Teams frequently ask:
- Does testing archived biobank serum samples require competent authority approval under IVDR Chapter VI?
- When does a companion diagnostic (CDx) study require a full 45-day member state application versus a simple notification?
- What makes an IVD clinical study "interventional" under EU law?
- How do the European requirements compare to the U.S. FDA Investigational Device Exemption (IDE) diagnostic exemptions under 21 CFR 812.2(c)(3)?
Failing to classify an IVD performance study correctly carries severe operational and commercial consequences. Submitting an unnecessary full application burns weeks to months of administrative clock-time — up to 45 to 65 days of authorization review for interventional or companion-diagnostic studies — along with member state review fees where charged. Conversely, initiating a study without required authorization or notification violates IVDR Chapter VI, invalidates data needed for notified body Performance Evaluation Report (PER) conformity assessments, and triggers statutory enforcement actions across the European Union.
With the adoption of MDCG 2025-5 (Questions & Answers on IVDR Performance Studies) by the Medical Device Coordination Group and the formal European harmonization of EN ISO 20916:2024 under Commission Implementing Decision (EU) 2024/2625, the European regulatory architecture for IVD clinical performance studies is now fully codified.
Disambiguation Note: This guide covers statutory performance study classifications, competent authority applications, notifications, assessment timelines, safety reporting, and end-of-study disclosure under IVDR Chapter VI (Articles 57–77), MDCG 2025-5, and MDCG 2024-4. It does not cover general Performance Evaluation Report (PER) drafting or Scientific Validity / Analytical Performance documentation (detailed in our IVDR Performance Evaluation Guide and EU MDR & IVDR Complete Guide), notified body consultation files for companion diagnostics (detailed in our IVDR CDx Consultation File Guide), or general medical device clinical investigation sponsor obligations under MDR Articles 62–82 (detailed in our MDR Clinical Investigation Guide).
Direct Answer to Core Scenario: If your team is planning an IVD study in the European Union utilizing human specimens:
- Full Competent Authority Application (IVDR Article 58 & Article 66): You must submit a formal dossier and obtain affirmative member state authorization only if the study meets one of four strict triggers:
- Surgically invasive sample-taking is performed solely for the purpose of the performance study (Article 58(1)(a));
- It is an interventional clinical performance study where test results may influence patient management decisions or guide medical treatment (Article 58(1)(b) & Article 2(46));
- Study conduct subjects participants to additional invasive procedures or other clinical risks (Article 58(1)(c)); or
- The study evaluates a companion diagnostic (CDx) without using exclusively leftover samples (Article 58(2)).
- Notification Route (IVDR Article 58(2) or Article 70(1)): You must submit a prior notification (not a full application) in two specific cases:
- Companion diagnostic (CDx) performance studies that utilize only leftover specimens (Article 58(2)); or
- Post-market performance follow-up (PMPF) studies on CE-marked IVDs evaluated within their intended purpose that subject participants to additional invasive or burdensome procedures beyond normal clinical practice, submitted at least 30 calendar days before study commencement (Article 70(1)).
- Neither EU Application nor EU Notification: Analytical and clinical performance studies conducted on leftover, anonymized, or banked specimens for non-CDx assays (where results do not guide patient care) require neither a Chapter VI application nor an EU-level notification. However, sponsors must adhere to national biobank, data privacy (GDPR), and local ethics committee requirements per MDCG 2025-5 Q15/Q17.
- Article 66 Timeline: Application-route studies face a 10-calendar-day completeness check by the national competent authority, followed by a statutory 45-calendar-day decision clock from the formal validation date (extendable by 20 days for expert consultation). Important exception: studies falling solely under Article 58(1)(a) whose specimen collection does not present a major clinical risk to subjects may start immediately after the validation date, without waiting for the 45-day authorization decision (Article 66(7)(a)).
- Post-Approval Obligations: Substantial modifications require notification and a 38-day earliest implementation window (Article 71). End of study requires notification within 15 calendar days (or 24 hours for safety halts) under Article 73. Serious adverse events (SAEs) with a causal link must be reported without delay under Article 76 using the MDCG 2024-4 reporting form, utilizing the interim CIV-ID single identification number until the EUDAMED performance study module is operational.
What Counts as a Performance Study Under IVDR Article 2?
To navigate European IVD clinical compliance, sponsors must first master the statutory taxonomy established in Chapter I and Chapter VI of Regulation (EU) 2017/746.
+----------------------------------------------------------------------------------------------------+
| IVDR CHAPTER VI PERFORMANCE STUDY TAXONOMY |
+----------------------------------------------------------------------------------------------------+
| |
| PERFORMANCE EVALUATION (Article 56) |
| The overarching continuous process of establishing: |
| [1] Scientific Validity --> [2] Analytical Performance --> [3] Clinical Performance |
| | |
| v |
| PERFORMANCE STUDY (Article 2(42)) |
| "A study undertaken to establish or confirm the analytical or clinical performance of a device" |
| |
| +-------------------------------------+--------------------------------------------------------+ |
| | SPECIMEN STUDY (Non-Interventional) | INTERVENTIONAL CLINICAL PERFORMANCE STUDY (Art 2(46)) | |
| | - Leftover routine samples | - Results influence clinical management | |
| | - Biobank / archived specimens | - Results guide patient treatment | |
| | - Non-invasive collection | - Treatment withheld / modified based on assay | |
| | - No treatment decisions made | - Test arm randomized against established practice | |
| +-------------------------------------+--------------------------------------------------------+ |
| |
+----------------------------------------------------------------------------------------------------+
Statutory Definitions
Under IVDR Article 2:
- Performance Study (Article 2(42)): “A study undertaken to establish or confirm the analytical or clinical performance of a device.” This encompasses all prospective and retrospective studies utilizing human specimens to generate analytical data (e.g., limit of detection, precision, analytical specificity, cross-reactivity) or clinical performance data (e.g., diagnostic sensitivity, diagnostic specificity, positive predictive value, negative predictive value).
- Clinical Performance Study: The IVDR does not define this as a separate term in Article 2. It is understood as a performance study within the meaning of Article 2(42) that is undertaken to establish or confirm the clinical performance of a device, as defined in Article 2(41) — the ability of a device to yield results correlated with a particular clinical condition or physiological/pathological process or state.
- Interventional Clinical Performance Study (Article 2(46)): “A clinical performance study where the test results may influence patient management decisions and/or may be used to guide treatment.”
- Subject (Article 2(47)): “An individual who participates in a performance study and whose specimen(s) undergo in vitro examination by a device for performance study and/or by a device used for control purposes.”
- Device for Performance Study (Article 2(45)): “A device intended by the manufacturer to be used in a performance study.” A device intended to be used for research purposes, without any medical objective, is not deemed a device for performance study.
General Legal Principles (Article 57)
Under IVDR Article 57, all performance studies—regardless of whether they require a competent authority application, notification, or neither—must comply with fundamental safeguards:
- Device conformity (Article 57(1)): The manufacturer must ensure the device for performance study complies with the general safety and performance requirements (GSPRs) of Annex I, apart from the aspects covered by the study, and that every precaution is taken to protect the health and safety of patients, users, and other persons with regard to those aspects.
- Realistic conditions (Article 57(2)): Where appropriate, performance studies must be performed in circumstances similar to the normal conditions of use of the device.
- Subject protection and data quality (Article 57(3)): Studies must be designed and conducted so that the rights, safety, dignity, and well-being of subjects are protected and prevail over all other interests, and so that the data generated are scientifically valid, reliable, and robust. Data protection law applies to all performance studies, expressly including those using leftover samples.
- Ethical anchoring: The recitals to the IVDR align the performance-study rules with the most recent version of the World Medical Association's Declaration of Helsinki; the application dossier under Annex XIV must contain a statement of compliance with recognized ethical principles and the principles of good clinical practice in the field of clinical performance studies. EN ISO 20916:2024 is the harmonized standard that codifies those good-study-practice principles (see the standards section below).
Application, Notification, or Neither? The IVDR Decision Tree
The core operational dilemma for IVD sponsors is determining the exact regulatory pathway under IVDR Chapter VI. Unlike pharmaceutical trials or MDR Class III implant investigations, the majority of IVD performance studies do not require competent authority authorization.
The following decision flowchart maps the statutory requirements of Articles 58(1), 58(2), and 70(1) as interpreted by MDCG 2025-5 (Appendix I):
+----------------------------------------------------------------------------------------------------+
| IVDR CHAPTER VI PERFORMANCE STUDY REGULATORY PATHWAY DECISION TREE |
+----------------------------------------------------------------------------------------------------+
| |
| [ START: Planned In Vitro Diagnostic Performance Study in EU Member State ] |
| | |
| v |
| [ QUESTION 1: Is it a Post-Market Performance Follow-Up (PMPF) study on a CE-marked IVD? ] |
| Is the device CE-marked and used strictly within its cleared/approved intended purpose? |
| | | |
| YES NO |
| v v |
| [ Q1a: Additional Burdensome Procedures? ] [ QUESTION 2: Is it a Companion Diagnostic (CDx)? ]
| Does the PMPF study submit subjects to Does the assay identify patients eligible for a |
| additional invasive or burdensome procedures? specific targeted medicinal therapy? |
| | | | | |
| YES NO YES NO |
| v v v v |
| +----------------+ +---------------+ [ Q2a: Leftover Only? ] [ QUESTION 3 ] |
| | ARTICLE 70(1) | | NO EU FILING | Are ONLY leftover specimens [ Four Triggers ] |
| | NOTIFICATION | | (Routine PMPF | utilized in the CDx study? | |
| | 30-Day Notice | | QMS record) | | | | |
| +----------------+ +---------------+ YES NO | |
| v v | |
| +-------------+ +---------------+ | |
| | ART 58(2) | | ARTICLE 58(2) | | |
| | NOTIFICATION| | APPLICATION | | |
| | Leftover CDx| | Full Art 66 | | |
| +-------------+ +---------------+ | |
| v |
| +----------------------------------------------------------------------------------------------+ |
| | QUESTION 3: Do any of the Three Core Article 58(1) Triggers Apply? | |
| | | |
| | [A] Surgically invasive sample-taking performed SOLELY for the study? (Art 58(1)(a)) | |
| | (e.g., blood draw, lumbar puncture, biopsy collected exclusively for this assay study) | |
| | [B] Interventional clinical performance study? (Art 58(1)(b) & Art 2(46)) | |
| | (Test results guide therapy, alter patient management, or assign treatment arms) | |
| | [C] Additional invasive procedures or other risks for subjects? (Art 58(1)(c)) | |
| | (e.g., extra radiation, pharmacological challenge, invasive monitoring) | |
| +----------------------------------------------------------------------------------------------+ |
| | | |
| YES to ANY Trigger NO to ALL Triggers |
| v v |
| =========================================== ================================================ |
| FULL COMPETENT AUTHORITY APPLICATION NEITHER EU APPLICATION NOR EU NOTIFICATION |
| - IVDR Article 58(1) & Article 66 Dossier - Leftover / archived sample analytical study |
| - 10-Day Completeness Check - Non-interventional clinical performance study |
| - 45-Day Decision Clock (+20 Day Extension) - Ethics & National Biobank laws still apply |
| - Formal CA Authorization & Ethics Approval - ISO 20916 Good Study Practice applies |
| =========================================== ================================================ |
| |
+----------------------------------------------------------------------------------------------------+
Pathway Comparison Table
The table below summarizes the regulatory classifications, legal bases, submission requirements, and assessment timelines across all IVDR Chapter VI performance study categories:
| Study Category | Statutory Citation | Submission Type | Filing Mechanism | Statutory Review Timeline | Ethics Committee Requirement |
|---|---|---|---|---|---|
| Surgically Invasive Sampling Solely for Study | Art. 58(1)(a) & Art. 66 | Full Application | CA Portal / EUDAMED (CIV-ID) | 10-day validation; immediate start after validation where sampling poses no major clinical risk (Art. 66(7)(a), MDCG 2025-5 Q25), otherwise 45 days (+20-day extension) | Mandatory positive opinion (Art. 58(3)) |
| Interventional Study (Results Guide Care) | Art. 58(1)(b) & Art. 66 | Full Application | CA Portal / EUDAMED (CIV-ID) | 10-day validation + 45 days (+20 day extension) | Mandatory positive opinion (Art. 58(3)) |
| Study Involving Additional Subject Risks | Art. 58(1)(c) & Art. 66 | Full Application | CA Portal / EUDAMED (CIV-ID) | 10-day validation + 45 days (+20 day extension) | Mandatory positive opinion (Art. 58(3)) |
| Companion Diagnostic (Prospective / Non-Leftover) | Art. 58(2) & Art. 66 | Full Application | CA Portal / EUDAMED (CIV-ID) | 10-day validation + 45 days (+20 day extension) | Mandatory positive opinion (Art. 58(3)) |
| Companion Diagnostic (Leftover Samples Only) | Art. 58(2) | Prior Notification | CA National Portal | Immediate / Member State acknowledgment | Governed by national law (MDCG 2025-5 Q17) |
| PMPF on CE-Marked IVD with Invasive/Burdensome Procedures | Art. 70(1) | Prior Notification | CA National Portal | At least 30 calendar days before study start | Governed by national law / Ethics review |
| PMPF on CE-Marked IVD without Added Burden | Art. 56 & Annex XIII | None (QMS Record) | Internal QMS / PMPF Plan | No prior CA filing required | Governed by national law / Local ethics |
| Specimen-Only Analytical Study (Leftover Samples) | Art. 57 | None | Internal Study File (ISO 20916) | No prior CA filing required | National biobank & consent law (MDCG 2025-5 Q15) |
What Makes a Study "Interventional" — The Article 2(46) Definition in Practice
The boundary between an observational specimen study and an interventional clinical performance study is one of the most critical legal determinations under IVDR.
Under IVDR Article 2(46), an interventional clinical performance study is defined as:
“A clinical performance study where the test results may influence patient management decisions and/or may be used to guide treatment.”
Operational Criteria for Interventional Status
A performance study is legally classified as interventional if any of the following clinical conditions occur:
- Direct Therapeutic Guidance: Investigational assay results dictate whether a subject receives a drug, surgical procedure, radiation therapy, or immunotherapy (e.g., a novel liquid biopsy assay used to allocate oncology patients to targeted therapies).
- Withholding or Altering Established Therapy: An investigational test result causes standard medical management, established therapeutic interventions, or confirmatory diagnostic testing to be withheld, delayed, or substituted.
- Escalation or De-escalation Protocols: Patient surveillance intervals, chemotherapy dosages, or immunosuppressive drug titration are adjusted based on investigational test readouts.
- Randomized Diagnostic Strategies: Patients are randomized between an arm where management is guided by the investigational IVD and a control arm guided by standard clinical chemistry or imaging.
+----------------------------------------------------------------------------------------------------+
| INTERVENTIONAL VS. OBSERVATIONAL DIAGNOSTIC STUDY DESIGNS |
+----------------------------------------------------------------------------------------------------+
| |
| [ OBSERVATIONAL / SPECIMEN STUDY ] [ INTERVENTIONAL PERFORMANCE STUDY ] |
| (Article 2(46) & Article 58(1)(b)) |
| |
| Subject --> Standard Care --> Diagnosis/Therapy Subject --> Investigational IVD Test Result |
| | | |
| +--> Specimen Collection (Leftover/Routine) v |
| | Directly Dictates: |
| v - Drug Selection / Dosage |
| Investigational IVD Assay - Surgical vs Medical Management |
| | - Escalation / De-escalation |
| v | |
| Data Logged for Performance Only v |
| (NO IMPACT ON PATIENT CARE) PATIENT CLINICAL OUTCOMES ALTERED |
| |
| ==> NO Full Application Required (Art 57) ==> FULL ARTICLE 58/66 APPLICATION MANDATORY |
| |
+----------------------------------------------------------------------------------------------------+
When Is a Study with Prospective Collection NOT Interventional?
If human specimens are prospectively collected, but the test results are blinded, batched, or generated post-hoc without disclosure to the treating physician, the study is not an interventional clinical performance study under Article 2(46).
However, beware of the other Article 58(1) triggers: if the prospective collection required a blood draw or biopsy performed solely for the study, it still requires a full application under Article 58(1)(a), even though it is not interventional under 58(1)(b).
Leftover Samples: What Qualifies and What It Exempts You From (MDCG 2025-5 Q30/Q31)
Leftover specimens represent the vast majority of analytical and clinical validation samples in IVD assay development. Clarifying their legal status under IVDR was a primary objective of MDCG 2025-5.
What Counts as a Leftover Sample?
Under MDCG 2025-5 Question 30, leftover samples are defined as:
“Unadulterated remnants of human derived specimens collected as part of routine clinical practice, for research purposes or other purposes not connected to the clinical performance study in question and after all standard or intended analyses have been performed. Such specimens/samples would be otherwise discarded as there is no remaining clinical need for the individual from which it was collected.”
Samples for which a clinical need remains — for example, where they are used in an interventional performance study — cannot be considered leftover samples (Q30).
Key characteristics of qualifying leftover samples include:
- Origin: Collected originally for routine clinical pathology, screening, standard patient workup, or clinical monitoring.
- Independence: The sample volume, collection timing, and sampling method were determined strictly by medical necessity, with zero modification for the planned performance study.
- Archival & Biobanks: Leftover specimens may be obtained fresh from clinical laboratories or retrieved from institutional biobanks, specimen repositories, or commercial vendor cohorts.
+----------------------------------------------------------------------------------------------------+
| LEFTOVER VS. STUDY-SPECIFIC SPECIMEN CRITERIA |
+----------------------------------------------------------------------------------------------------+
| |
| CRITERION LEFTOVER SPECIMEN (Residual) STUDY-SPECIFIC COLLECTION |
| ---------------------------- --------------------------------- ------------------------------ |
| Primary Purpose of Draw Routine Patient Care / Diagnosis Solely for Performance Study |
| Draw Volume Standard Clinical Volume Extra Tube / Volume Added |
| Timing of Collection Driven by Medical Need Driven by Study Protocol |
| If Study Cancelled? Specimen Discarded as Medical Waste Specimen Never Collected |
| |
| IVDR Legal Classification Specimen-Only (Art. 57) Surgically Invasive (58(1)(a)) |
| Competent Authority Filing NONE (EU Level) FULL APPLICATION (Art. 66) |
| |
+----------------------------------------------------------------------------------------------------+
What Leftover Status Exempts You From
Under MDCG 2025-5 Question 15 and Question 31:
- Studies utilizing exclusively leftover samples for non-companion diagnostic IVDs do not trigger Article 58(1)(a) (since no invasive sampling was performed solely for the study).
- Provided the test results are not used to guide patient treatment (avoiding Article 58(1)(b)) and no added risks are imposed on subjects (avoiding Article 58(1)(c)), no competent authority application or EU notification is required under IVDR Chapter VI.
Cautionary Exception (National Law Reservation): MDCG 2025-5 Q17 explicitly warns that “national requirements may apply regarding notifications or ethics committee approvals for studies using left-over samples.” For example, national biobank acts, human tissue acts (e.g., in France, Germany, or the Netherlands), and broad-consent opt-out registries may require local ethics committee notification or specific patient consent before secondary specimen research can proceed.
Companion Diagnostic (CDx) Studies: When Full Applications vs. Notifications Apply (Article 58(2))
Companion diagnostics represent a uniquely regulated class of in vitro diagnostics under IVDR. Under IVDR Article 2(7), a companion diagnostic is defined as a device essential for the safe and effective use of a corresponding medicinal product to identify patients likely to benefit from the therapy or identify patients likely to be at increased risk of serious adverse reactions.
Because CDx assays are tightly coupled to pharmaceutical clinical trials, IVDR Article 58(2) establishes a dedicated bifurcated regime:
+----------------------------------------------------------------------------------------------------+
| IVDR ARTICLE 58(2) COMPANION DIAGNOSTIC (CDx) STUDY REGIMES |
+----------------------------------------------------------------------------------------------------+
| |
| [ COMPANION DIAGNOSTIC PERFORMANCE STUDY UNDER EVALUATION ] |
| | |
| v |
| [ Specimen Source Assessment: Are ONLY leftover specimens utilized? ] |
| | |
| +----------------+----------------+ |
| | | |
| YES NO (Prospective collection / invasive draw) |
| v v |
| ====================================== ======================================================== |
| ARTICLE 58(2) NOTIFICATION ARTICLE 58(2) & ARTICLE 66 FULL APPLICATION |
| - Applicable to retrospective leftover - Mandatory for prospective patient stratification trials |
| CDx validation cohorts - Requires full Annex XIV Chapter I technical dossier |
| - Submitted to concerned Member States - 10-day completeness check + 45-day decision clock |
| - Governed by national filing rules - Must synchronize with Clinical Trials Regulation (CTR) |
| - No 45-day statutory approval clock - Electronic system interoperability with CTIS (Art. 69) |
| ====================================== ======================================================== |
| |
+----------------------------------------------------------------------------------------------------+
Co-Development with Pharmaceutical Trials (CTR 536/2014 & IVDR Interoperability)
When a companion diagnostic performance study is embedded within a drug clinical trial governed by the Clinical Trials Regulation (Regulation (EU) No 536/2014 - CTR):
- Dual Authorization: The clinical trial of the medicinal product is authorized via the Clinical Trials Information System (CTIS) under CTR 536/2014, while the companion diagnostic performance study must be authorized or notified under IVDR Article 58/66.
- Interoperability Mandate (Article 69): IVDR Article 69 requires the future EUDAMED performance study electronic system to be interoperable with the CTIS database.
- Leftover Exception in Drug Trials: If archived biopsy specimens from patients already enrolled in a clinical drug trial are retrospectively tested with an investigational CDx to evaluate biomarker concordance, the study qualifies as a leftover CDx study under Article 58(2) and requires only a notification rather than a separate Article 66 application.
For detailed requirements on the notified body consultation file for approved CDx devices, refer to our comprehensive guide on IVDR Companion Diagnostic Consultation Files.
The Article 66 Application Workflow: Dossier, 10-Day Completeness Check, and the 45-Day Decision Clock
When a performance study meets one of the Article 58 triggers, the sponsor must execute the formal application workflow set forth in IVDR Article 66.
+----------------------------------------------------------------------------------------------------+
| IVDR ARTICLE 66 APPLICATION TIMELINE AND MILESTONES |
+----------------------------------------------------------------------------------------------------+
| |
| DAY 0 SPONSOR SUBMISSION |
| - Submits Annex XIV Chapter I dossier via national CA portal / EUDAMED |
| - System assigns single identification number (CIV-ID) |
| | |
| v |
| DAYS 1-10 COMPLETENESS & SCOPE CHECK (Article 66(1) & 66(3)) |
| - Member State checks IVDR scope & Annex XIV completeness |
| | |
| +-----------+-----------+ |
| | | |
| COMPLETE INCOMPLETE |
| | | |
| v v |
| VALIDATION DATE DEFICIENCY NOTICE (Article 66(2)) |
| (Clock Starts: T=0) - Sponsor given 10 days to respond (extendable by up to 20 days) |
| | - Application lapses if no response submitted |
| | | |
| | Deficiencies Resolved ==> VALIDATION DATE FIXED |
| +-----------------------+ |
| | |
| v |
| EXCEPTION: 58(1)(a)-ONLY STUDY, SAMPLING POSES NO MAJOR CLINICAL RISK? |
| ==> MAY START IMMEDIATELY AFTER VALIDATION (Article 66(7)(a); factors per |
| MDCG 2025-5 Q25: study population, subjects' clinical status, number, |
| volume and type of samples) - provided no valid negative ethics opinion |
| | |
| v |
| DAYS 1-45 AUTHORIZATION ASSESSMENT CLOCK (Article 66(7)(b)) |
| (From - National Competent Authority evaluates Annex XIV technical documentation |
| Validation - Safety, analytical validity, benefit-risk balance, risk management |
| Date) | |
| +-----------------------------------+ |
| | | |
| STANDARD REVIEW EXPERT CONSULTATION EXTENSION |
| | (Article 66(7) second subparagraph) |
| | - CA may extend clock by up to +20 DAYS |
| | - Total assessment window: up to 65 DAYS |
| v v |
| DAY 45 / 65 FINAL AUTHORIZATION DECISION |
| - Member State notifies sponsor of its authorization decision |
| - Ethics Committee positive opinion must be confirmed (Article 58(3)) |
| - STUDY MAY COMMENCE |
| |
+----------------------------------------------------------------------------------------------------+
Application Dossier Contents (Annex XIV, Chapter I)
Under IVDR Annex XIV Chapter I, a full performance study application dossier must include:
- Application Form: Standardized European application form containing sponsor identity, legal representative in the EU (if sponsor is outside the EU per Article 58(4)), device description, intended purpose, and performance study classification.
- Performance Study Plan (PSP): Comprehensive protocol complying with Annex XIII Part A Section 2 and EN ISO 20916:2024, including study rationale, primary/secondary endpoints, sample size statistical justification, inclusion/exclusion criteria, specimen collection procedures, and monitoring plans.
- Investigator’s Brochure (IB): Complete pre-clinical and analytical evidence dossier detailing assay design, analytical sensitivity, specificity, interference limits, risk analysis, and instructions for use.
- Subject Information and Informed Consent Form: Documentation complying with Articles 59–65 and national language requirements.
- Ethics Committee Documentation: Copy of opinion(s) or submission proof in accordance with national law.
- Investigational Device Description & Manufacturing Records: Evidence of device conformity with applicable general safety and performance requirements (GSPRs) outside the scope of the study.
- Facilities and Investigator Suitability: Proof of investigator qualification and laboratory accreditation (e.g., ISO 15189 / CLIA certification).
For the harmonized set of application and notification document templates, MDCG 2025-5 Question 36 points sponsors to MDCG 2022-19 (performance study application/notification documents) and to the website of the relevant national competent authority for member-state-specific application content requirements; the annexes of EN ISO 20916:2024 provide additional content guidance for some required documents.
Detailed Chronological Clock Breakdown
- Day 0: Dossier submitted by sponsor.
- Day 10 (Completeness Check, Art. 66(1)): The Member State notifies the sponsor whether the study falls within the scope of IVDR and the dossier is complete.
- Deficiency Clock (Art. 66(2)): If incomplete, the Member State sets a deadline of maximum 10 calendar days for the sponsor to comment or complete the dossier. The sponsor may request an extension of up to 20 calendar days. If the sponsor fails to respond, the application lapses.
- Validation Date: The date the sponsor is officially notified that the dossier is valid and complete.
- Day 45 Post-Validation (Authorisation Decision, Art. 66(7)(b)): The Member State must notify the sponsor of its authorization decision within 45 calendar days from the validation date.
- Expert Extension (+20 Days, Art. 66(7)(b)): The Member State may extend the 45-day review period by an additional 20 calendar days to consult external scientific experts.
- Immediate Start for Low-Risk 58(1)(a) Studies (Art. 66(7)(a)): A study that falls solely under Article 58(1)(a) and whose specimen collection does not represent a major clinical risk to subjects may be started immediately after the validation date, provided no negative ethics opinion valid for the entire Member State is in force. Per MDCG 2025-5 Question 25, the major-clinical-risk assessment considers the study population, the clinical status of subjects, and the number, volume, and type of samples collected — and sponsors are encouraged to document their justification in the application. The 45-day authorization clock in Article 66(7)(b) applies to all other application-route studies (Article 58(1)(b), 58(1)(c), and 58(2)).
PMPF Studies on CE-Marked IVDs: The 30-Day Notification Rule (Article 70)
Post-Market Performance Follow-Up (PMPF) is a continuous process governed by IVDR Article 56 and Annex XIII Part B. When a manufacturer conducts a prospective clinical performance study to further confirm the performance of a device that already bears a valid CE mark, IVDR Article 70 governs the regulatory filing.
+----------------------------------------------------------------------------------------------------+
| IVDR ARTICLE 70(1) PMPF NOTIFICATION WORKFLOW |
+----------------------------------------------------------------------------------------------------+
| |
| [ CE-MARKED IVD CONDUCTED WITHIN ITS CLEARED INTENDED PURPOSE ] |
| | |
| v |
| [ Do study procedures submit subjects to additional invasive or burdensome procedures? ] |
| (e.g., extra blood draws, biopsy, additional imaging, invasive monitoring) |
| | |
| +----------------+----------------+ |
| | | |
| YES NO |
| v v |
| ====================================== ======================================================== |
| ARTICLE 70(1) PMPF NOTIFICATION NO COMPETENT AUTHORITY FILING |
| - Submit notification at least 30 DAYS - Conduct study under internal QMS & PMPF Plan |
| before study commencement - Maintain data in Technical Documentation |
| - Attach Annex XIII Part A Sec.2 docs - Submit to Notified Body during annual surveillance |
| plus Annex XIV documents - Local ethics review if required by national law |
| - Ethics committee opinion per national law |
| - Comply with Articles 71, 72, 73; safety reporting for |
| PMPF studies runs through the vigilance rules of |
| Articles 82-85 (per Article 76(5)) |
| ====================================== ======================================================== |
| |
+----------------------------------------------------------------------------------------------------+
What Constitutes an "Invasive or Burdensome" Procedure?
Under MDCG 2025-5 Question 32, additional procedures are burdensome when they may cause pain, discomfort, fear, potential risks or complications and side effects, disturbances of the subject's life and personal activities, or otherwise unpleasant experiences — and the assessment is made primarily from the perspective of the person bearing the burden. Question 27 adds that invasive procedures include (but are not limited to) any penetration inside the body through the surface of the body or through mucous membranes of body orifices, including invasive procedures unrelated to specimen collection (e.g., gastroscopy), and that for PMPF studies the burdensomeness test of Q32 must be considered alongside invasiveness.
Applying those criteria, procedures that typically count as additional invasive or burdensome procedures include:
- Performing additional venipunctures solely for the PMPF study that would not occur during standard medical management;
- Requiring extra tissue core biopsies during a surgical resection;
- Imposing additional radiological scans (e.g., CT, MRI) or radioactive tracer administrations;
- Requiring extended patient hospital stays or frequent clinic visits outside standard disease follow-up.
Legal Effect of Article 70(1) Notification
Under Article 70(1):
- The sponsor must notify the concerned Member States at least 30 calendar days before commencement.
- The sponsor must include the documentation referenced in Section 2 of Part A of Annex XIII and in Annex XIV (Article 70(1)).
- The sponsor does not wait for an affirmative authorization letter; once 30 calendar days have elapsed and a favorable ethics committee opinion is obtained, the study may proceed unless the authority objects.
- Crucially, Articles 71 (substantial modifications), 72 (corrective measures), and 73 (end-of-study reporting) apply to Article 70(1) PMPF studies, together with points (b) to (l) and (p) of Article 58(5). Safety reporting for PMPF studies follows the vigilance rules of Articles 82–85 rather than the in-study Article 76 regime (Article 76(5)) — Article 76 applies to a PMPF study only where a causal relationship between a serious adverse event and the preceding performance study has been established (Article 76(6)).
For device-side PMCF study parallels under EU MDR, consult our guide to Post-Market Clinical Follow-Up (PMCF) Under EU MDR.
Substantial Modifications: The 1-Week Notice and 38-Day Assessment Clock (Article 71)
Once a performance study is authorized under Article 58 or notified under Article 70(1), any proposed protocol amendments must be evaluated against the statutory definition of a substantial modification.
What Is a Substantial Modification?
Under IVDR Article 71(1), a modification is substantial if it is likely to have a substantial impact on:
- The safety, health, or rights of the subjects; or
- The robustness or reliability of the clinical data generated by the study.
MDCG 2025-5 Appendix II provides an authoritative, non-exhaustive list of substantial modifications:
- Changes to primary or secondary endpoints, clinical hypothesis, or diagnostic cutoff values;
- Modifications to inclusion/exclusion criteria that broaden the patient population or include vulnerable populations (e.g., pediatric subjects, pregnant women);
- Addition of new invasive sample-taking procedures or increased specimen volumes;
- Alteration of assay reagent formulation, target antigens, or critical analytical software algorithms;
- Addition of new clinical study sites or changes in principal investigators;
- Changes to the sponsor’s legal representative or study monitoring plan.
+----------------------------------------------------------------------------------------------------+
| IVDR ARTICLE 71 SUBSTANTIAL MODIFICATION ASSESSMENT CLOCK |
+----------------------------------------------------------------------------------------------------+
| |
| DAY 0 SPONSOR SUBMITS SUBSTANTIAL MODIFICATION NOTIFICATION |
| - Submits updated Annex XIV documents & rationale within 1 WEEK of change decision |
| | |
| v |
| DAYS 1-38 STATUTORY 38-DAY ASSESSMENT WINDOW (Article 71(3)) |
| - Member State assesses impact on subject safety and data integrity |
| - Ethics Committee evaluates amendment per national law |
| | |
| +-----------+-----------+ |
| | | |
| NO OBJECTION OBJECTION / REFUSAL / NEGATIVE ETHICS OPINION |
| | | |
| v v |
| DAY 38 EARLIEST MODIFICATION BLOCKED |
| IMPLEMENTATION - Sponsor cannot implement amendment |
| - Sponsor implements - Must address competent authority / ethics objections |
| modified protocol |
| |
+----------------------------------------------------------------------------------------------------+
Statutory Clocks under Article 71
- 1-Week Notice (Art. 71(1)): The sponsor must notify the concerned Member States within one week of determining that a modification is substantial.
- 38-Day Implementation Window (Art. 71(3)): The sponsor may implement the modifications at the earliest 38 calendar days after notification, unless:
- A concerned Member State refuses the modification on the grounds referred to in Article 67(4) or on considerations of public health, subject and user safety or health, or public policy; or
- An ethics committee issues a negative opinion in accordance with national law.
- Expert Extension (+7 Days, Art. 71(4)): The Member State may extend the 38-day period by a further 7 calendar days for expert consultation.
End-of-Study, Temporary Halts, and Early Termination Reporting (Article 73)
Public transparency and timely reporting of study milestones are core tenets of IVDR Chapter VI. IVDR Article 73 mirrors the end-of-study disclosure rules of MDR Article 77.
+----------------------------------------------------------------------------------------------------+
| IVDR ARTICLE 73 STUDY CLOSURE AND REPORTING TIMELINES |
+----------------------------------------------------------------------------------------------------+
| |
| STUDY EVENT STATUTORY NOTIFICATION DEADLINE RECIPIENT & MECHANISM |
| --------------------------------- ------------------------------- --------------------------- |
| Temporary Halt for SAFETY Grounds Within 24 HOURS All Concerned Member States |
| Early Termination for SAFETY Within 24 HOURS All Concerned Member States |
| Temporary Halt (Non-Safety) Within 15 CALENDAR DAYS All Concerned Member States |
| Early Termination (Non-Safety) Within 15 CALENDAR DAYS All Concerned Member States |
| Standard Study End in Member State Within 15 CALENDAR DAYS Concerned Member State |
| Overall Study End (Multi-State) Within 15 CALENDAR DAYS All Concerned Member States |
| |
| ================================================================================================ |
| POST-STUDY DELIVERABLE STATUTORY DEADLINE PUBLIC RELEASE (Art. 73(7)) |
| --------------------------------- ------------------------------- --------------------------- |
| Full Performance Study Report Within 1 YEAR of Study End Public in EUDAMED upon CE |
| (Annex XIII Part A Section 2.3.3) (3 MONTHS if halted/terminated) mark or 1 yr post-entry |
| --------------------------------- ------------------------------- --------------------------- |
| Report Summary Within 1 YEAR of Study End Public in EUDAMED upon CE |
| (Easily understandable to (3 MONTHS if halted/terminated) mark or 1 yr post-entry |
| the intended user) |
| |
+----------------------------------------------------------------------------------------------------+
Key Milestones under Article 73
- Definition of Study End (Art. 73(2)): A performance study ends with the last visit of the last subject, unless a different endpoint (e.g., completion of all central laboratory assay runs) is explicitly defined in the Performance Study Plan.
- The 24-Hour Safety Halt Clock (Art. 73(1)): If a study is temporarily halted or terminated early on safety grounds (e.g., unexpected cross-reactivity causing incorrect clinical decisions), the sponsor must notify all concerned Member States within 24 hours.
- The 15-Day General End-of-Study Clock (Art. 73(1) & 73(3)): Standard completion or non-safety halts must be notified to each concerned Member State within 15 calendar days.
- Performance Study Report & Summary (Art. 73(5)-(7)): The sponsor must submit a comprehensive Performance Study Report (PSR) complying with Annex XIII Part A Section 2.3.3, accompanied by a summary presented in terms easily understandable to the intended user, within 1 year of study completion (reduced to 3 months if the study was terminated early or temporarily halted). Both documents are published in EUDAMED once the IVD is CE-marked; if the device is not registered within one year of entry into the electronic system, they become publicly accessible at that point.
For reciprocal requirements governing clinical trial registry disclosures on ClinicalTrials.gov and EUDAMED, refer to our comprehensive guide on ClinicalTrials.gov Registration and Results Reporting for Medical Devices.
Safety Reporting Under Article 76 and the MDCG 2024-4 Form
Safety reporting in IVD performance studies differs substantially from therapeutic drug trials or surgical implant studies. Because many IVD studies involve in vitro examination of specimens, device-related adverse events often stem from sample collection procedures or diagnostic errors leading to inappropriate medical management.
What Must Be Recorded and Reported (Article 76(1))
Under IVDR Article 76(1), the sponsor must fully record:
- All adverse events (AEs) identified in the Performance Study Plan as critical to the evaluation of study results;
- All serious adverse events (SAEs);
- All device deficiencies that might have led to a serious adverse event if appropriate action had not been taken, if intervention had not occurred, or if circumstances had been less fortunate;
- Any new findings relating to any reportable event.
Reportable Events to Competent Authorities (Article 76(2))
The sponsor must report to all concerned Member States:
- Any SAE that has a causal relationship with the investigational device, a comparator, or study procedure, or where such relationship is reasonably possible;
- Any device deficiency that might have led to an SAE;
- Any reportable SAE occurring in third countries under the same Performance Study Plan.
+----------------------------------------------------------------------------------------------------+
| IVDR ARTICLE 76 SAFETY REPORTING PATHWAY |
+----------------------------------------------------------------------------------------------------+
| |
| ADVERSE EVENT DETECTED DURING PERFORMANCE STUDY |
| | |
| v |
| [ Is the event a SERIOUS ADVERSE EVENT (SAE) or qualifying Device Deficiency? ] |
| - Death, life-threatening illness/injury, permanent impairment, hospitalization, |
| or fetal distress / congenital abnormality |
| | |
| +----------------+----------------+ |
| | | |
| YES NO |
| v v |
| [ Causal Relationship Assessment ] LOG IN STUDY RECORDS (Non-critical AE) |
| Is causality with device, comparator, - Retain in Trial Master File (TMF) |
| or procedure confirmed or REASONABLY - Include in final Performance Study Report |
| POSSIBLE? |
| | | |
| YES NO |
| v v |
| MANDATORY ARTICLE 76 LOG IN STUDY FILE |
| SAFETY REPORTING - Retain causality justification |
| - Submit without delay via - Include in cumulative safety log |
| MDCG 2024-4 Form |
| - Report to ALL concerned |
| EU Member States |
| |
+----------------------------------------------------------------------------------------------------+
The MDCG 2024-4 Reporting Template & Historical Transition
Under MDCG 2025-5 Question 13, sponsors must utilize the standardized MDCG 2024-4 safety reporting form and summary table.
Furthermore, MDCG 2025-5 Question 14 clarifies a vital historical transition rule:
- Performance studies approved or initiated before 26 May 2022 under the legacy In Vitro Diagnostic Directive (Directive 98/79/EC - IVDD) do not need to be resubmitted under IVDR.
- However, any SAE or qualifying device deficiency occurring after 26 May 2022 in an ongoing legacy study must be reported under IVDR Article 76.
For detailed side-by-side comparison of device safety reporting clocks under 21 CFR 812.150 and MDR Article 80, see our Medical Device Trial Safety Reporting Guide.
Multi-Country Studies: Specimen Collection vs. Central Lab Analysis Across Member States (MDCG 2025-5 Q20/Q44)
In modern diagnostic clinical trials, study workflows are frequently split across borders: patient recruitment and specimen collection occur in several EU Member States, while assay analysis is centralized in a single specialized laboratory located in another Member State.
MDCG 2025-5 resolved how Chapter VI applies to these cross-border architectures in Questions 20 and 44.
+----------------------------------------------------------------------------------------------------+
| CROSS-BORDER MULTI-STATE STUDY ARCHITECTURE (MDCG 2025-5 Q20 / Q44) |
+----------------------------------------------------------------------------------------------------+
| |
| MEMBER STATE A (Recruitment & Specimen Draw) MEMBER STATE B (Central Diagnostic Lab) |
| - Patient enrolled and consented - Receives coded, blinded specimen aliquots |
| - Blood draw solely for study (Art 58(1)(a)) - Runs investigational IVD analyzer |
| |
| =========================================== =============================================== |
| REGULATORY OBLIGATIONS: REGULATORY OBLIGATIONS: |
| - Submit full Article 58/66 Application - Article 57 applies (Ethical/Scientific Baselines)
| - Obtain National CA Authorization - NO Article 58 Application required in MS B |
| - Obtain Positive Ethics Committee Opinion - Sponsor verifies laboratory accreditation |
| =========================================== =============================================== |
| |
| STUDY COMMENCEMENT RULE (Q44): |
| The study may start in Member State A as soon as Member State A authorises the study and the |
| sponsor confirms the central laboratory in Member State B is operational and qualified. |
| |
+----------------------------------------------------------------------------------------------------+
Multi-State Decision Rules
- Where to Submit Article 58 Applications (Q20): Full Article 58 applications must be submitted to the competent authorities of Member States where subjects are located and specimens are collected.
- Analysis-Only Member States (Q20): In Member States hosting only central testing laboratories (where no human subjects undergo sampling), no Article 58 application is required; only the general principles of Article 57 apply.
- Sequenced Study Start (Q44): In a multi-center study involving Member States A, B, and C, the study can commence in Member State A as soon as Member State A grants authorization and ethics approval, provided the central testing laboratory is ready, without waiting for pending authorizations in Member States B or C.
Operational Infrastructure: CIV-ID, National Portals, and the EUDAMED Performance Study Gap
Under IVDR Article 69, the European Commission is mandated to establish an electronic system for performance studies to manage applications, notifications, substantial modifications, safety reports, and study results across the EU.
However, as detailed in our guide on the May 2026 EUDAMED Mandatory Registration Deadlines, while four core EUDAMED modules (Actor, UDI/Device, Notified Bodies/Certificates, Market Surveillance) become mandatory in 2026, the Clinical Investigations and Performance Studies module remains under development.
+----------------------------------------------------------------------------------------------------+
| INTERIM SUBMISSION ARCHITECTURE (MDCG 2025-5 Q35) |
+----------------------------------------------------------------------------------------------------+
| |
| EUDAMED MODULE STATUS INTERIM OPERATIONAL ROUTING |
| --------------------------------- ------------------------------------------------------------- |
| EUDAMED CI/PS Module NOT YET FUNCTIONAL |
| |
| Single Identification Number CIV-ID (Generated by Competent Authorities via Eudamed2) |
| Alongside National Application Reference Numbers |
| |
| Application & Notification Filing National Competent Authority Portals: |
| - Germany: BfArM / DIMDI DMIDS Portal |
| - Netherlands: CCMO / ToetsingOnline Portal |
| - France: ANSM Portal |
| - Denmark: Danish Medical Products Agency (DMP) |
| - Finland: FIMEA Performance Study Desk |
| |
| Safety Reporting Routing Direct email / portal submission to national CAs using |
| the standardized MDCG 2024-4 XML / Excel summary form |
| |
+----------------------------------------------------------------------------------------------------+
Under MDCG 2025-5 Question 35:
- Sponsors must obtain a CIV-ID (the single European identifier generated through Eudamed2) from the national competent authority during initial application.
- All subsequent safety reports under Article 76, substantial modifications under Article 71, and end-of-study notices under Article 73 must reference this CIV-ID.
- Once the EUDAMED performance study module is formally declared functional by Commission notice, all active studies will migrate to the centralized portal.
EN ISO 20916:2024 Harmonization vs. ISO 20916:2019 Good Study Practice
In IVD performance studies, ISO 20916 serves as the diagnostic equivalent of ISO 14155 (which governs general medical device clinical investigations). Regulatory professionals must understand the critical distinction between the international standard and its European harmonized counterpart.
+----------------------------------------------------------------------------------------------------+
| ISO 20916:2019 VS. EN ISO 20916:2024 ARCHITECTURE |
+----------------------------------------------------------------------------------------------------+
| |
| INTERNATIONAL STANDARD EUROPEAN HARMONIZED STANDARD |
| ISO 20916:2019 EN ISO 20916:2024 |
| "Good Study Practice for IVD Studies" (Adopted by CEN / Harmonized under IVDR) |
| |
| +-------------------------------------+ +---------------------------------------------------+ |
| | TECHNICAL CORE (Unchanged) | | TECHNICAL CORE (Identical to ISO 20916:2019) | |
| | - Ethical considerations & consent | | - Ethical considerations & consent | |
| | - Performance Study Plan (PSP) | | - Performance Study Plan (PSP) | |
| | - Sponsor & Investigator duties | | - Sponsor & Investigator duties | |
| | - Specimen collection & management | | - Specimen collection & management | |
| | - Clinical Performance Study Report | | - Clinical Performance Study Report | |
| +-------------------------------------+ +---------------------------------------------------+ |
| | |
| +-------------------------v-------------------------+ |
| | ANNEX ZA (European Legal Bridge) | |
| | Maps standard clauses to: | |
| | - IVDR General Safety & Performance Req (GSPR) | |
| | - IVDR Annex XIII (Performance Evaluation) | |
| | - IVDR Annex XIV (Performance Studies) | |
| +---------------------------------------------------+ |
| | |
| ==========================v========================== |
| PRESUMPTION OF CONFORMITY (Implementing Decision 2024/2625)
| Confers legal presumption of conformity with IVDR |
| requirements covered in Annex ZA |
| ===================================================== |
| |
+----------------------------------------------------------------------------------------------------+
Key Technical Aspects of ISO 20916
- Systematic Review Confirmation: ISO 20916:2019 was confirmed unchanged at ISO stage 90.93 (International Standard confirmed, 6 February 2025) following its five-year systematic review.
- Harmonization under Implementing Decision (EU) 2024/2625: On 8 October 2024, the European Commission adopted Commission Implementing Decision (EU) 2024/2625, published in the Official Journal on 9 October 2024, harmonizing EN ISO 20916:2024 under Regulation (EU) 2017/746.
- Presumption of Conformity: Compliance with EN ISO 20916:2024 confers a formal legal presumption of conformity with the corresponding IVDR Chapter VI and Annex XIII/XIV requirements mapped in European Annex ZA.
- Three Study Categories in ISO 20916: The standard structures quality management around three operational study types:
- Interventional clinical performance studies;
- Non-interventional clinical performance studies with study-specific sample collection;
- Studies using leftover specimens.
For comparison with general medical device GCP standards, see our guide on ISO 14155 Clinical Investigations for Medical Devices.
How the U.S. Pathway Differs: The 21 CFR 812.2(c)(3) Diagnostic Device IDE Exemption
Multinational diagnostic manufacturers frequently design validation protocols intended to satisfy both European IVDR requirements and U.S. FDA premarket submissions (such as a 510(k) Premarket Notification or Premarket Approval). Understanding the U.S. investigational framework under 21 CFR Part 812 is essential.
The Four Conditions of 21 CFR 812.2(c)(3)
In the United States, an investigational in vitro diagnostic device is completely exempt from the formal Investigational Device Exemption (IDE) regulations under 21 CFR 812.2(c)(3) (with the sole exception of 812.119 investigator disqualification) if the sponsor complies with 21 CFR 809.10(c) investigational labeling and the study satisfies all four statutory conditions:
+----------------------------------------------------------------------------------------------------+
| U.S. FDA 21 CFR 812.2(c)(3) DIAGNOSTIC DEVICE IDE EXEMPTION TEST |
+----------------------------------------------------------------------------------------------------+
| |
| [ CONDITION 1: NONINVASIVE TESTING ] |
| The testing is noninvasive (applied to specimens outside the body). |
| | |
| YES |
| v |
| [ CONDITION 2: NO SIGNIFICANT-RISK SAMPLING ] |
| Does NOT require an invasive sampling procedure that presents significant risk to the subject. |
| (Standard venipuncture is generally non-significant risk; deep core biopsy is significant risk) |
| | |
| YES |
| v |
| [ CONDITION 3: NO ENERGY INTRODUCTION ] |
| Does NOT by design or intention introduce energy into a subject. |
| | |
| YES |
| v |
| [ CONDITION 4: NOT USED AS DIAGNOSTIC PROCEDURE WITHOUT CONFIRMATION ] |
| The assay is NOT used as a diagnostic procedure without confirmation by another medically |
| established diagnostic product or procedure. |
| | |
| YES |
| v |
| ================================================================================================ |
| RESULT: EXEMPT FROM 21 CFR PART 812 IDE REGULATIONS |
| - No FDA IDE submission required |
| - Comply with 21 CFR 809.10(c) labeling ("For Investigational Use Only...") |
| - Institutional Review Board (IRB) review & informed consent per 21 CFR Parts 50 & 56 apply |
| ================================================================================================ |
| |
+----------------------------------------------------------------------------------------------------+
Transatlantic Regulatory Comparison Table
| Regulatory Dimension | European Union (IVDR 2017/746 Chapter VI) | United States (FDA 21 CFR Part 812) |
|---|---|---|
| Exempt / Routine Specimen Studies | Leftover specimen studies exempt from CA application/notification (Art. 57) | Studies meeting all 4 conditions of 21 CFR 812.2(c)(3) exempt from IDE |
| Routine Blood Sampling | Surgically invasive sampling solely for study triggers Full Application (Art. 58(1)(a)) | Routine venipuncture generally treated as Exempt or Non-Significant Risk (NSR) |
| Interventional / Unconfirmed Results | Test results guiding patient care trigger Full Application (Art. 58(1)(b)) | Unconfirmed results guiding care violate 812.2(c)(3)(iv) ==> Full IDE Required |
| Companion Diagnostics (CDx) | Leftover CDx = Notification (58(2)); Non-leftover CDx = Full Application | Significant-risk CDx in drug trial = Full IDE; Leftover CDx = IDE Exempt / NSR |
| Statutory Review Clocks | 10-day completeness + 45-day review (+20 day extension) | 30-calendar-day FDA review clock for IDE applications |
| Clinical Trial Registration | Required in EUDAMED (CIV-ID interim); published post-CE mark (Art. 73) | Mandatory on ClinicalTrials.gov within 21 days if Applicable Device Clinical Trial |
For detailed operational guidance on U.S. investigational device filings, see our Medical Device IDE Guide and Informed Consent in Medical Device Clinical Trials Guide.
IVDR Performance Studies vs. MDR Clinical Investigations: Side-by-Side Comparison
Device manufacturers managing portfolios that span both hardware devices and diagnostic assays must navigate two distinct clinical chapters: MDR Chapter VI (Articles 62–82) and IVDR Chapter VI (Articles 57–77).
+----------------------------------------------------------------------------------------------------+
| MDR CLINICAL INVESTIGATION VS. IVDR PERFORMANCE STUDY COMPARISON |
+----------------------------------------------------------------------------------------------------+
| |
| FEATURE EU MDR (Regulation 2017/745) EU IVDR (Regulation 2017/746) |
| ---------------------------- ----------------------------------- ----------------------------- |
| Primary Biological Interface Direct physical contact with subject In vitro testing on specimens |
| Default Regulatory Posture Full Application for non-CE devices Specimen studies often exempt |
| Core Standard EN ISO 14155:2020 EN ISO 20916:2024 |
| Post-Market Clinical Study Article 74(1) PMCF Notification Article 70(1) PMPF Notification|
| Safety Reporting Clock Article 80 (Severity-based) Article 76 (MDCG 2024-4 Form) |
| End of Study Report Deadline Article 77 (1 Year / 3 Months) Article 73 (1 Year / 3 Months) |
| Interim Identifier CIV-ID / National Reference CIV-ID / National Reference |
| |
+----------------------------------------------------------------------------------------------------+
Real-World IVD Evidence Landscape: ClinicalTrials.gov Registry Analysis (2026)
To quantify the real-world operational landscape of diagnostic evidence generation, MedDeviceGuide analyzed live aggregate data from the National Library of Medicine’s ClinicalTrials.gov API v2 on 22 August 2026.
+----------------------------------------------------------------------------------------------------+
| CLINICALTRIALS.GOV DIAGNOSTIC TEST STUDY REGISTRY ANALYSIS (2026) |
+----------------------------------------------------------------------------------------------------+
| |
| TOTAL REGISTERED STUDIES WITH DIAGNOSTIC_TEST INTERVENTION: 19,386 |
| |
| +------------------------------------------------+---------------------------------------------+ |
| | INTERVENTIONAL STUDIES | OBSERVATIONAL / SPECIMEN STUDIES | |
| | 7,337 Studies (37.85%) | 12,040 Studies (62.11%) | |
| | - Test results guide treatment | - Retrospective biobank cohorts | |
| | - Randomized diagnostic utility arms | - Prospective specimen collection | |
| | - Active clinical management altered | - Blinded analytical & clinical validation | |
| +------------------------------------------------+---------------------------------------------+ |
| |
+----------------------------------------------------------------------------------------------------+
Dataset Methodology and Key Findings
- Search Parameters: Filtered on
AREA[InterventionType]DIAGNOSTIC TESTacross all registered studies in the ClinicalTrials.gov API v2 database as of 22 August 2026. - Interventional vs. Observational Split: Of the 19,386 total registered diagnostic studies, 12,040 (62.11%) are observational in design, while 7,337 (37.85%) are interventional.
- Regulatory Takeaway: Over 62% of diagnostic clinical investigations focus on observational specimen evaluations. Under IVDR Chapter VI, the vast majority of these studies utilize leftover or non-interventional prospective specimens and thus fall outside the burdensome Article 58 full-application mandate.
Data source: Live ClinicalTrials.gov API v2 aggregate query executed 2026-08-22. Note: Diagnostic test classifications in ClinicalTrials.gov reflect sponsor-entered parameters and include diagnostic modalities evaluated in pharmaceutical clinical protocols.
Sponsor Compliance Playbook: 6 Operational Pitfalls and SOP Checklists
To prevent costly regulatory delays and compliance enforcement actions, IVD sponsors should embed the following six operational controls into their standard operating procedures (SOPs):
+----------------------------------------------------------------------------------------------------+
| IVDR PERFORMANCE STUDY SPONSOR COMPLIANCE PLAYBOOK |
+----------------------------------------------------------------------------------------------------+
| |
| [ PITFALL 1: INADVERTENT SURGICALLY INVASIVE TRIGGER ] |
| SOP Control: Ensure specimen collection protocols for analytical studies rely strictly on |
| leftover clinical volume. Never add an extra blood draw tube exclusively for the assay study |
| without budgeting for an Article 58(1)(a) full application. |
| |
| [ PITFALL 2: UNINTENDED INTERVENTIONAL CLASSIFICATION ] |
| SOP Control: If validating a diagnostic algorithm, explicitly blind treating clinicians to assay |
| readouts. Document in the Performance Study Plan that test results are never disclosed or used |
| for patient management decisions. |
| |
| [ PITFALL 3: COMPANION DIAGNOSTIC OVERSIGHT ] |
| SOP Control: Screen all biomarker development protocols. If an assay stratifies oncology |
| patients in a prospective drug trial, initiate Article 58(2) filings concurrently with CTIS. |
| |
| [ PITFALL 4: SUBSTANTIAL MODIFICATION CLOCK BREACH ] |
| SOP Control: Freeze all protocol and software changes until the statutory 38-day Article 71 |
| assessment window has elapsed and national ethics approvals are secured. |
| |
| [ PITFALL 5: MISALIGNED MULTI-STATE RECRUITMENT ] |
| SOP Control: Sequence site activations per MDCG 2025-5 Q44. Open collection sites in authorized |
| Member States immediately while waiting for secondary country authorisations. |
| |
| [ PITFALL 6: SAFETY REPORTING DELAYS ] |
| SOP Control: Deploy the MDCG 2024-4 reporting template. Train site investigators to log and |
| escalate specimen-collection SAEs and diagnostic-failure false negatives within 24 hours. |
| |
+----------------------------------------------------------------------------------------------------+
Frequently Asked Questions (FAQs)
Do all IVDR performance studies need competent authority approval?
No. Competent authority authorization under IVDR Article 58 and Article 66 is required only for four specific categories: (1) surgically invasive sample collection conducted solely for the study, (2) interventional clinical performance studies where results influence patient care, (3) studies involving additional invasive procedures or risks for subjects, and (4) companion diagnostic studies that do not use exclusively leftover samples. Specimen-only studies using leftover samples do not require EU-level competent authority approval.
Does a study on leftover samples need an application or notification?
Under EU-level IVDR rules (Articles 57 and 58), non-companion diagnostic studies using exclusively leftover routine clinical samples require neither a full application nor a prior notification, provided test results do not guide patient treatment. However, companion diagnostic studies on leftover samples require a prior notification under Article 58(2), and national biobank or ethics committee rules may apply in individual Member States per MDCG 2025-5 Q17.
How long does member state authorization take under Article 66?
Once an application is submitted, the competent authority has 10 calendar days to validate the dossier's completeness. From the validation date, the statutory decision clock is 45 calendar days. The authority may extend this assessment period by up to 20 additional calendar days if external scientific experts are consulted, resulting in a maximum review window of 65 days (plus the initial 10-day validation). One important exception: a study falling solely under Article 58(1)(a) whose specimen collection does not present a major clinical risk may start immediately after the validation date under Article 66(7)(a), without waiting for the 45-day authorization decision.
Do IVDD-era studies that started before 26 May 2022 need to be resubmitted?
No. Under MDCG 2025-5 Question 14, performance studies approved or initiated prior to 26 May 2022 under the legacy IVD Directive (98/79/EC) may continue without resubmission under IVDR. However, any serious adverse events or reportable device deficiencies occurring after 26 May 2022 must be reported in compliance with IVDR Article 76.
Is a performance study with a CE-marked IVD within its intended purpose a study requiring an application?
No. A post-market performance follow-up (PMPF) study evaluating a CE-marked IVD within its cleared intended purpose never requires an Article 58 application. If the study subjects participants to additional invasive or burdensome procedures beyond standard care, it requires a 30-calendar-day prior notification under Article 70(1). If no additional burden is imposed, no competent authority filing is required.
What is the CIV-ID and when will EUDAMED replace it?
The CIV-ID is a single identification number generated by national competent authorities via Eudamed2 to track medical device investigations and IVD performance studies across the EU. Because the EUDAMED Clinical Investigations and Performance Studies module is still under development, sponsors must obtain and reference this CIV-ID for all interim national submissions until the centralized EUDAMED module is formally declared functional.
Do IVD performance studies need ethics committee review under IVDR?
Yes. Under IVDR Article 58(3), performance studies are subject to scientific and ethical review by an ethics committee in accordance with national law — this applies to all performance studies, not only those requiring an application. For application-route studies, a negative ethics opinion that is valid for the entire Member State blocks commencement (Article 66(7)). For leftover specimen studies, national law dictates whether institutional ethics review or biobank committee exemption applies.
Is ISO 20916 mandatory for IVDR performance studies?
While standards are technically voluntary under European law, compliance with EN ISO 20916:2024 (harmonized under Commission Implementing Decision (EU) 2024/2625) provides a formal presumption of conformity with IVDR Chapter VI and Annex XIII/XIV performance study requirements. Notified bodies and competent authorities treat ISO 20916 as the benchmark for Good Study Practice.
References and Primary Legal Authorities
- Regulation (EU) 2017/746 (IVDR): Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices (Chapter VI, Articles 57–77, Annex XIII, Annex XIV).
- MDCG 2025-5: Medical Device Coordination Group: Questions & Answers on IVDR Performance Studies (Adopted June 2025).
- MDCG 2024-4: Safety reporting in performance studies of in vitro diagnostic medical devices under Regulation (EU) 2017/746.
- Commission Implementing Decision (EU) 2024/2625: Harmonised standards for in vitro diagnostic medical devices in support of Regulation (EU) 2017/746 (EN ISO 20916:2024).
- U.S. Code of Federal Regulations: 21 CFR Part 812 — Investigational Device Exemptions, Section 812.2(c)(3) Diagnostic Device Exemption.
- U.S. Code of Federal Regulations: 21 CFR 809.10(c) — In Vitro Diagnostic Products for Human Use, Labeling for Investigational Devices.
- ISO 20916:2019: In vitro diagnostic medical devices — Clinical performance studies using specimens from human subjects — Good study practice.
- Regulation (EU) No 536/2014 (CTR): Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use (Articles 1 & 2).